NQO1 activation regulates angiotensin-converting enzyme shedding in spontaneously hypertensive rats

Cardiovascular Research

Volumn 99, Issue 4, 2013, Pages 743-750

  Kim, Yong Hoon ^a   Hwang, Jung Hwan ^a   Kim, Kyung Shim ^a   Noh, Jung Ran ^a   Gang, Gil Tae ^a   Kim, Sang Woo ^a   Jang, Seung Pil ^b   Lee, Sang Ju ^c   Her, Sung Ho ^c   Jeong, Kyeong Hoon ^d   Kwak, Tae Hwan ^e   Park, Woo Jin ^b   Balyasnikova, Irina V ^f   Shong, Minho ^g   Lee, Chul Ho ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Gachon University College of Medicine   (South Korea)

^e R and D Center KT and G Life Sciences Corp   (South Korea)

^f UNIVERSITY OF CHICAGO   (United States)

^g Chungnam National University   (South Korea)

Author keywords

Angiotensin converting enzyme; Blood pressure; CaMKII; NQO1

Indexed keywords

ANGIOTENSIN II; BETA LAPACHONE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; RYANODINE RECEPTOR; SMALL INTERFERING RNA; THREONINE; UNCLASSIFIED DRUG;

ANGIOTENSIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; CELL LINE; CHELATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME RELEASE; ESSENTIAL HYPERTENSION; IN VITRO STUDY; INHIBITION KINETICS; MALE; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN-CONVERTING ENZYME; BLOOD PRESSURE; CAMKII; NQO1;

ANIMALS; BLOOD PRESSURE; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELLS, CULTURED; HUMANS; HYPERTENSION; MALE; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; PEPTIDYL-DIPEPTIDASE A; PHOSPHORYLATION; RATS; RATS, INBRED SHR;

EID: 84883211697     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt147     Document Type: Article

References (58)

1. Soffer RL. Angiotensin-converting enzyme and the regulation of vasoactive peptides. Annu Rev Biochem 1976;45:73-94.
2. Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res 2006;98:887-896.
3. Antonaccio MJ. Angiotensin converting enzyme (ACE) inhibitors. Annu Rev Pharmacol Toxicol 1982;22:57-87.
4. Ferrario CM, Jaiswal N, Yamamoto K, Diz DI, Schiavone MT. Hypertensive mechanisms and converting enzyme inhibitors. Clin Cardiol 1991;14:IV56-IV62; discussion IV83-90.
5. Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, CapecchiMR et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997;99:2375-2385.
6. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES et al. Malefemale differences in fertility and blood pressure in ACE-deficient mice. Nature 1995; 375:146-148.
7. Esther CR Jr, Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996;74:953-965.
8. Corvol P, Williams TA, Soubrier F. Peptidyl dipeptidase A: angiotensin I-converting enzyme. Methods Enzymol 1995;248:283-305.
9. Caldwell PR, Seegal BC, Hsu KC, Das M, Soffer RL. Angiotensin-converting enzyme: vascular endothelial localization. Science 1976;191:1050-1051.
10. Ramchandran R, Sen I. Cleavage processing of angiotensin-converting enzyme by a membrane-associated metalloprotease. Biochemistry 1995;34:12645-12652.
11. Ramchandran R, Kasturi S, Douglas JG, Sen I. Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells. Am J Physiol 1996;271:H744-H751.
12. Li J, Hu HY, Zhao YN. Serum angiotensin-converting enzyme activity in pregnancy-induced hypertension. Gynecol Obstet Invest 1992;33:138-141.
13. O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ et al. Evidence for association and genetic linkage of the angiotensin- converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998;97:1766-1772.
14. Higaki J, Baba S, Katsuya T, Sato N, Ishikawa K, Mannami T et al. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. Circulation 2000;101:2060-2065.
15. Di Pasquale P, Cannizzaro S, Paterna S. Does angiotensin-converting enzyme gene polymorphism affect blood pressure? Findings after 6 years of follow-up in healthy subjects. Eur J Heart Fail 2004;6:11-16.
16. NgKK, Vane JR. Conversion of angiotensin I to angiotensin II. Nature 1967;216:762-766.
17. Cai H, Liu D, Garcia JG. CaM Kinase II-dependent pathophysiological signalling in endothelial cells. Cardiovasc Res 2008;77:30-34.
18. Griffith LC. Calcium/calmodulin-dependent protein kinase II: an unforgettable kinase. J Neurosci 2004;24:8391-8393.
19. Colbran RJ, Smith MK, Schworer CM, Fong YL, Soderling TR. Regulatory domain of calcium/calmodulin-dependent protein kinase II. Mechanism of inhibition and regulation by phosphorylation. J Biol Chem 1989;264:4800-4804.
20. Chattopadhyay S, Santhamma KR, Sengupta S, McCue B, Kinter M, Sen GC et al. Calmodulin binds to the cytoplasmic domain of angiotensin-converting enzyme and regulates its phosphorylation and cleavage secretion. J Biol Chem 2005;280: 33847-33855.
21. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129:77-97.
22. Nioi P, Hayes JD. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res 2004;555:149-171.
23. Kim YH, Hwang JH, Noh JR, Gang GT, Kim do H, Son HY et al. Activation of NAD(P)H:-quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity. Cardiovasc Res 2011;91:519-527.
24. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER et al. Modulation of soluble receptor for advanced glycation end products by angiotensinconverting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005;16: 2363-2372.
25. Votta-Velis EG, Minshall RD, Visintine DJ, Castellon M, Balyasnikova IV. Propofol attenuates endotoxin-induced endothelial cell injury, angiotensin-converting enzyme shedding, and lung edema. Anesth Analg 2007;105:1363-1370, table of contents.
26. Lu CS, Hodge JJ, Mehren J, Sun XX, Griffith LC. Regulation of the Ca2+/CaM-responsive pool of CaMKII by scaffold-dependent autophosphorylation. Neuron 2003;40: 1185-1197.
27. De Flora A, Zocchi E, Guida L, Franco L, Bruzzone S. Autocrine and paracrine calcium signaling by the CD38/NAD+/cyclic ADP-ribose system. Ann NY Acad Sci 2004;1028: 176-191.
28. Guse AH. Second messenger function and the structure-activity relationship of cyclic adenosine diphosphoribose (cADPR). FEBS J 2005;272:4590-4597.
29. Lesh RE, Marks AR, Somlyo AV, Fleischer S, Somlyo AP. Anti-ryanodine receptor antibody binding sites in vascular and endocardial endothelium. Circ Res 1993;72: 481-488.
30. Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 2004;94: e61-e70.
31. Sadhukhan R, Sen GC, Ramchandran R, Sen I. The distal ectodomain of angiotensinconverting enzyme regulates its cleavage-secretion from the cell surface. Proc Natl Acad Sci USA 1998;95:138-143.
32. Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: amajor risk factor and a marker of risk for coronary stent restenosis. Circulation 1998;97: 147-154.
33. Nagi DK, Foy CA, Mohamed-Ali V, Yudkin JS, Grant PJ, Knowler WC. Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians. Metabolism 1998;47:622-626.
34. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF et al. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994;90:669-676.
35. Kreutz R, Hubner N, Ganten D, Lindpaintner K. Genetic linkage of the ACE gene to plasma angiotensin-converting enzyme activity but not to blood pressure.Aquantitative trait locus confers identical complex phenotypes in human and rat hypertension. Circulation 1995;92:2381-2384.
36. Parkin ET, Tan F, Skidgel RA, Turner AJ, Hooper NM. The ectodomain shedding of angiotensin-converting enzyme is independent of its localisation in lipid rafts. J Cell Sci 2003;116:3079-3087.
37. Santhamma KR, Sadhukhan R, Kinter M, Chattopadhyay S, McCue B, Sen I. Role of tyrosine phosphorylation in the regulation of cleavage secretion of angiotensin-converting enzyme. J Biol Chem 2004;279:40227-40236.
38. Kohlstedt K, Shoghi F, Muller-Esterl W, Busse R, Fleming I. CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res 2002;91:749-756.
39. Kohlstedt K, Kellner R, Busse R, Fleming I. Signaling via the angiotensin-converting enzyme results in the phosphorylation of the nonmuscle myosin heavy chain IIA. Mol Pharmacol 2006;69:19-26.
40. Xiao HD, Fuchs S, Frenzel K, Teng L, Bernstein KE. Circulating versus local angiotensin II in blood pressure control: lessons from tissue-specific expression of angiotensin-converting enzyme (ACE). Crit Rev Eukaryot Gene Expr 2004;14: 137-145.
41. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-1052.
42. Muller DN, Bohlender J, Hilgers KF, Dragun D, Costerousse O, Menard J et al. Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Hypertension 1997;29:98-104.
43. Cole J, Quach DL, Sundaram K, Corvol P, Capecchi MR, Bernstein KE. Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure. Circ Res 2002;90: 87-92.
44. Cole JM, Khokhlova N, Sutliff RL, Adams JW, Disher KM, ZhaoHet al. Mice lacking endothelial ACE: normal blood pressure with elevated angiotensin II. Hypertension 2003;41: 313-321.
45. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
46. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996;58:1268-1278.
47. Oosterga M, Voors AA, de Kam PJ, Schunkert H, Pinto YM, Kingma JH et al. Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation 1997;95:2607-2609.
48. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880.
49. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978;240: 1607-1610.
50. Dyer AR, Elliott P. The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Co-operative Research Group. J Hum Hypertens 1989;3: 299-308.
51. Jiang J, Kitano T, Shono M, Wakamiya J, Futatsuka M. Serial study on the association between body mass index and hypertension in rural Japanese. Environ Health Prev Med 2003;8:90-94.
52. CooperR, McFarlane-Anderson N, Bennett FI, Wilks R, Puras A,TewksburyDet al.ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 1997;11:107-111.
53. Harp JB, Henry SA, DiGirolamo M. Dietary weight loss decreases serum angiotensinconverting enzyme activity in obese adults. Obes Res 2002;10:985-990.
54. Appel LJ, Champagne CM,HarshaDW, CooperLS, Obarzanek E, Elmer PJ et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003;289:2083-2093.
55. Lefevre M, Redman LM, Heilbronn LK, Smith JV, Martin CK, RoodJC et al. Caloric restriction alone and with exercise improvesCVDrisk in healthy non-obese individuals. Atherosclerosis 2009;203:206-213.
56. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
57. Chen D, Bruno J, Easlon E, Lin SJ, Cheng HL, Alt FW et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev 2008;22:1753-1757.
58. Chan D, Ng LL. Biomarkers in acute myocardial infarction. BMC Med 2010;8:34.